Adularia AG

Adularia is a preclinical biotech spin-off from the University of Zurich developing novel small molecule cancer immunotherapies. The research of the symbiotic interplay between gut microbes and the immune system led to the identification of GPR84 as a novel therapeutic target for immuno-oncology. We have developed several series of proprietary small-molecule modulators of GPR84 and showed that these molecules are able to reprogram myeloid cells in cancer, causing an enhanced anti-tumor immune response. By replicating this natural mechanism with a synthetic small molecule, we aim to deliver a highly effective, targeted, and well-tolerated cancer treatment. We are advancing toward IND-enabling studies by mid-2027 and are currently raising seed funding to complete our preclinical program.